Back

Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

29 August 2025 (14:40 - 14:50)
Organised by: Logo
Congress Presentation Part of: What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy? Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Rodica Pop-Busui

Oregon Health and Science University, Portland (United States of America)

5 More presentations in this session

Presentation thumbnail
Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial
Doctor J. Plutzky (Boston, US)
Abstract Slides Video
Presentation thumbnail
Vagal activity related events and GLP-1 receptor agonists
Mr A. Holt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population
Ms K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effects of SGLT2 inhibitors on triglyceride-derived indices among coronary heart disease patients with varying diabetes control status: a prospective cohort study
Professor N. Wu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 14:40 CET
You may be interested in
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources